NCT05760612 2025-09-25
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting